150 related articles for article (PubMed ID: 23433742)
1. Endometrial cancer: molecular and therapeutic aspects.
Tsikouras P; Bouchlariotou S; Vrachnis N; Dafopoulos A; Galazios G; Csorba R; von Tempelhoff GF
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):1-9. PubMed ID: 23433742
[TBL] [Abstract][Full Text] [Related]
2. Current issues in the management of endometrial cancer.
Bakkum-Gamez JN; Gonzalez-Bosquet J; Laack NN; Mariani A; Dowdy SC
Mayo Clin Proc; 2008 Jan; 83(1):97-112. PubMed ID: 18174012
[TBL] [Abstract][Full Text] [Related]
3. Management of endometrial cancer.
Fowler W; Mutch D
Womens Health (Lond); 2008 Sep; 4(5):479-89. PubMed ID: 19072487
[TBL] [Abstract][Full Text] [Related]
4. New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
Rodriguez-Freixinos V; Karakasis K; Oza AM
Curr Oncol Rep; 2016 Apr; 18(4):23. PubMed ID: 26922329
[TBL] [Abstract][Full Text] [Related]
5. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
6. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
[TBL] [Abstract][Full Text] [Related]
7. Classification of endometrial carcinoma: more than two types.
Murali R; Soslow RA; Weigelt B
Lancet Oncol; 2014 Jun; 15(7):e268-78. PubMed ID: 24872110
[TBL] [Abstract][Full Text] [Related]
8. Genetic alterations in endometrial cancer by targeted next-generation sequencing.
Chang YS; Huang HD; Yeh KT; Chang JG
Exp Mol Pathol; 2016 Feb; 100(1):8-12. PubMed ID: 26626801
[TBL] [Abstract][Full Text] [Related]
9. Update on the chemotherapeutic management of endometrial cancer.
Bregar A; Robison K; Dizon DS
Clin Adv Hematol Oncol; 2014 Oct; 12(10):659-65. PubMed ID: 25658891
[TBL] [Abstract][Full Text] [Related]
10. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant treatment for stage IIIC endometrial cancer: options and controversies.
Shah PH; Kudrimoti M; Feddock J; Randall M
Gynecol Oncol; 2011 Sep; 122(3):675-83. PubMed ID: 21664661
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of spontaneous endometrial adenocarcinomas in BDII rats.
Samuelson E; Hedberg C; Nilsson S; Behboudi A
Endocr Relat Cancer; 2009 Mar; 16(1):99-111. PubMed ID: 19075038
[TBL] [Abstract][Full Text] [Related]
13. Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease.
Llauradó M; Ruiz A; Majem B; Ertekin T; Colás E; Pedrola N; Devis L; Rigau M; Sequeiros T; Montes M; Garcia M; Cabrera S; Gil-Moreno A; Xercavins J; Castellví J; Garcia A; Ramón y Cajal S; Moreno G; Alameda F; Vázquez-Levin M; Palacios J; Prat J; Doll A; Matías-Guiu X; Abal M; Reventós J
Mol Cell Endocrinol; 2012 Jul; 358(2):244-55. PubMed ID: 22037169
[TBL] [Abstract][Full Text] [Related]
14. Endometrial cancer: a review and current management strategies: part II.
; Burke WM; Orr J; Leitao M; Salom E; Gehrig P; Olawaiye AB; Brewer M; Boruta D; Herzog TJ; Shahin FA;
Gynecol Oncol; 2014 Aug; 134(2):393-402. PubMed ID: 24929052
[TBL] [Abstract][Full Text] [Related]
15. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma.
Ollikainen M; Gylling A; Puputti M; Nupponen NN; Abdel-Rahman WM; Butzow R; Peltomäki P
Int J Cancer; 2007 Aug; 121(4):915-20. PubMed ID: 17471559
[TBL] [Abstract][Full Text] [Related]
16. Expression and potential role of ErbB receptors in type II endometrial cancer.
Androutsopoulos G; Adonakis G; Liava A; Ravazoula P; Decavalas G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):204-8. PubMed ID: 23395558
[TBL] [Abstract][Full Text] [Related]
17. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
18. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
Mori N; Kyo S; Sakaguchi J; Mizumoto Y; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
Cancer Sci; 2007 Dec; 98(12):1881-8. PubMed ID: 17924977
[TBL] [Abstract][Full Text] [Related]
19. Advances in the treatment of endometrial cancer.
Oehler MK; Fung A; Jobling TW
J Br Menopause Soc; 2005 Mar; 11(1):18-22. PubMed ID: 15814058
[TBL] [Abstract][Full Text] [Related]
20. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
